Skip to main content

Table 3 Sensitivity analyses for association between low-dose aspirin use and cancer-specific mortality in lung cancer patients

From: Low-dose aspirin and survival from lung cancer: a population-based cohort study

 

Cancer-specific deaths

All patients

Person years

User versus non-user

User versus non-user

 

Unadjusted

P

Adjusted HRa

P

P for interaction

    

HRa

95 % CI

 

HRa

95 % CI

  

Main analysis: Aspirin user versus non-user after diagnosis

2,247

3,635

6,745

0.96

0.87, 1.05

0.36

0.96

0.85, 1.09

0.55

 

Sub group analyses: Aspirin user versus non-user after diagnosis, restricted to:

        

 Males

1,312

2,105

3,750

1.00

0.89, 1.12

0.97

1.05

0.90, 1.22

0.54

0.12

 Females

935

1,530

2,995

0.87

0.75, 1.02

0.08

0.81

0.66, 0.99

0.05

 Pre-diagnosis aspirin non-usersb

1,515

2,446

4,578

0.89

0.74, 1.07

0.21

0.91

0.73, 1.14

0.42

0.48

 Pre-diagnosis aspirin usersb

554

908

1,601

0.92

0.72, 1.16

0.47

1.02

0.77, 1.35

0.90

 Small cell lung cancer

328

424

592

0.84

0.66, 1.09

0.19

0.72

0.52, 1.01

0.05

0.03

 Non-small cell lung cancer

1,523

2,615

5,355

0.95

0.85, 1.06

0.35

1.00

0.86, 1.16

0.99

 Surgically treated

305

872

2,714

0.99

0.78, 1.27

0.96

0.95

0.71,1.28

0.74

0.39

 Non-surgically treated

820

1,708

4,216

0.94

0.80, 1.10

0.42

0.89

0.74, 1.07

0.22

Sensitivity analyses: Aspirin user versus non-user after diagnosis

        

 Increasing lag to 1 year

2,247

3,635

6,745

0.97

0.88, 1.07

0.56

0.97

0.85, 1.10

0.60

 

 Excluding patients who died within the first 6 months after diagnosis

4,440

6,158

9,101

0.96

0.90, 1.03

0.28

0.95

0.87–1.04

0.30

 

 Additionally adjusting for smoking prior to diagnosis

2037

3,315

6,074

0.95

0.86, 1.04

0.28

0.95

0.84, 1.08

0.41

 

 Additionally adjusting for BMI prior to diagnosis

1,849

3,048

5,640

0.93

0.84, 1.03

0.15

0.95

0.84, 1.09

0.47

 

 Additionally adjusting for small cell/non-small cell

1,851

3,039

5,947

0.92

0.83, 1.03

0.14

0.92

0.80, 1.05

0.23

 

 Based upon first year after diagnosisc

1,728

2,791

5,223

0.93

0.87, 1.05

0.33

0.99

0.88, 1.13

0.91

 

 Nested case–control analysisd,e

2,247

  

0.93

0.85, 1.03

0.19

1.00

0.86, 1.16

0.97

 
  1. aExcept where otherwise stated, all analyses of post-diagnostic aspirin use adjusted for year of diagnosis, age at diagnosis, gender, surgery within 6 months of diagnosis, radiotherapy within 6 months, chemotherapy within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates, specifically statins and beta-blockers) and deprivation (in fifths)
  2. bBased upon aspirin use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis
  3. cSimplified analysis, not requiring time varying covariate use, comparing aspirin users to aspirin non-users in the first year after diagnosis in individuals living more than 1 year after cancer diagnosis, adjusted for all confounders ina but other medication use also restricted to first year after diagnosis
  4. dUnadjusted OR estimate and 95 % CIs based on 28 % (623/2,247) of cancer-specific deaths using aspirin compared with 31 % (3,254/10,603) of risk-set controls (not dying from cancer)
  5. eAdjusted OR estimate and 95%CIs, matched on age at diagnosis, year of diagnosis, gender and adjusted for all other confounders ina
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us